NLRP3 and colitis: Their data showed that oral administration of CAI reduced colon disease severity in TNBS-colitis and this reduction was accompanied by reduced activation of NF-kB, as well as reduced activation of the NLRP3 inflammasome and production of pro-inflammatory cytokines in the inflamed colon.